US House passes crucial bill on defence co-operation with India

Agencies
July 15, 2017

Jul 15: The US House of Representatives has passed a dollor 621.5 billion defence expenditure bill that proposes to advance defence cooperation with India.usindia

An amendment in this regard, moved by Indian-American Congressman Ami Bera, was adopted by a voice vote by the House as part of the National Defense Authorisation Act (NDAA) 2018, beginning October 1 this year. NDAA-2018 was passed by the House 344-81.

The India-related amendment passed by the House requires the Secretary of Defence, in consultation with the Secretary of State, to develop a strategy for advancing defence cooperation between the United States and India.

"The United States is the worlds oldest democracy and India is the world's largest democracy. It is vitally important to develop a strategy that advances defence cooperation between our two nations," Bera said.

"I am grateful this amendment passed and look forward to the Defence Departments strategy that addresses critical issues like common security challenges, the role of partners and allies, and areas for collaboration in science and technology," he said.

Jul 15: The US House of Representatives has passed a dollor 621.5 billion defence expenditure bill that proposes to advance defence cooperation with India.

An amendment in this regard, moved by Indian-American Congressman Ami Bera, was adopted by a voice vote by the House as part of the National Defense Authorisation Act (NDAA) 2018, beginning October 1 this year. NDAA-2018 was passed by the House 344-81.

The India-related amendment passed by the House requires the Secretary of Defence, in consultation with the Secretary of State, to develop a strategy for advancing defence cooperation between the United States and India.

"The United States is the worlds oldest democracy and India is the world's largest democracy. It is vitally important to develop a strategy that advances defence cooperation between our two nations," Bera said.

"I am grateful this amendment passed and look forward to the Defence Departments strategy that addresses critical issues like common security challenges, the role of partners and allies, and areas for collaboration in science and technology," he said.

Cooperation enhances ability to meet security challenges

"Cooperation between the US and India enhances our own defence and our ability to meet the evolving security challenges of the 21st century," Bera said.

Following the passage of the National Defence Authorisation Act, the Secretary of Defence and Secretary of State have 180 days to develop a strategy for advancing defence cooperation between the United States and India. NDAA needs to be passed by the Senate before it can be sent to the White House for the US President Donald Trump to sign into law.

As passed by the House, NDAA-2018 asks the State Department and the Pentagon to develop a strategy that addresses common security challenges, the role of American partners and allies in India-US defence relationship, and role of the defence technology and trade initiative.

It also asks them to address how to advance the communications interoperability and security memorandum of agreement and the basic exchange and cooperation agreement for geospatial cooperation. The previous NDAA-2017 had designated India as a major defence partner which brings India at par with closest American partners in terms of defence trade and technology transfer.

Cooperation enhances ability to meet security challenges

Meanwhile, a senior defence official yesterday said that India and US defence relationship is on positive track.

"We look at the global order, and when we look at the evolving security environment within Asia, India's rise and role [is] evolving, [and] we see the United States and India increasingly viewing the region in the same way, and our interests are very much aligned," said Cara Abercrombie, Deputy Assistant Secretary of Defence for South and Southeast Asia.

Addressing a New York audience, she said the relationship creates a high level of dialogue in the Pentagon on a range of issues.

"This is all rooted in when we look at the region and [what] we share. We have the same [aerial] security interests, the same counter-proliferation, counter-piracy, and counter- terrorism [interests]," she added.

"We have the same interests in upholding this international system that upholds the rule of law that favours freedom of navigation, open sea lanes of communication, and freedom of over flight. Those are values that are critically important to the United States and India to our economic prosperity and to our access in the region," Abercrombie said during a panel discussion at the 2017 Global Business Forum in New York City.

"Cooperation between the US and India enhances our own defence and our ability to meet the evolving security challenges of the 21st century," Bera said.

Following the passage of the National Defence Authorisation Act, the Secretary of Defence and Secretary of State have 180 days to develop a strategy for advancing defence cooperation between the United States and India. NDAA needs to be passed by the Senate before it can be sent to the White House for the US President Donald Trump to sign into law.

As passed by the House, NDAA-2018 asks the State Department and the Pentagon to develop a strategy that addresses common security challenges, the role of American partners and allies in India-US defence relationship, and role of the defence technology and trade initiative.

It also asks them to address how to advance the communications interoperability and security memorandum of agreement and the basic exchange and cooperation agreement for geospatial cooperation. The previous NDAA-2017 had designated India as a major defence partner which brings India at par with closest American partners in terms of defence trade and technology transfer.

'India-us defence ties on positive track'

Meanwhile, a senior defence official yesterday said that India and US defence relationship is on positive track.

"We look at the global order, and when we look at the evolving security environment within Asia, India's rise and role [is] evolving, [and] we see the United States and India increasingly viewing the region in the same way, and our interests are very much aligned," said Cara Abercrombie, Deputy Assistant Secretary of Defence for South and Southeast Asia.

Addressing a New York audience, she said the relationship creates a high level of dialogue in the Pentagon on a range of issues.

"This is all rooted in when we look at the region and [what] we share. We have the same [aerial] security interests, the same counter-proliferation, counter-piracy, and counter- terrorism [interests]," she added.

"We have the same interests in upholding this international system that upholds the rule of law that favours freedom of navigation, open sea lanes of communication, and freedom of over flight. Those are values that are critically important to the United States and India to our economic prosperity and to our access in the region," Abercrombie said during a panel discussion at the 2017 Global Business Forum in New York City.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 10,2020

Paris, Apr 10: French pharma major Sanofi said on Friday it has decided to donate 100 million doses of hydroxychloroquine, the anti-malaria drug which could be a potential weapon against novel coronavirus, across 50 countries.

The company has already doubled its incremental production capacity on top of the usual production for current indications across its eight hydroxychloroquine manufacturing sites worldwide and is on track to quadruple it by the summer.

"In this global health emergency, Sanofi stands ready to assist as many countries as possible, starting with countries where its medicine is registered for current approved indications as well as countries where there are no hydroxychloroquine suppliers or countries with underserved populations," it said in a statement.

Sanofi called for coordination among the entire hydroxychloroquine chain worldwide to ensure the continued supply of the medicine if proven to be a well-tolerated and effective treatment in COVID-19 patients.

"The COVID-19 pandemic is an unprecedented health and economic crisis which is shaking some of the very fundamentals of international solidarity and cooperation among countries," said Chief Executive Officer Paul Hudson. "This virus does not care about the concept of borders, so we should not either," he added.

"It is critical that international authorities, local governments, manufacturers and all other players involved in the hydroxychloroquine chain work together in a coordinated manner to ensure all patients who may benefit from this potential treatment can access it. If the trials prove positive, we hope our donation will play a critical role for patients," said Hudson.

While hydroxychloroquine is generating a lot of hope for patients around the world, said Sanofi, it should be remembered that there are no results from ongoing studies and the results may be positive or negative.

To date, there is insufficient clinical evidence to draw any conclusion over the safety and efficacy of hydroxychloroquine in the management of COVID-19 patients.

It is one of several medicines being investigated by the World Health Organisation (WHO) in its international clinical trial seeking a treatment solution for COVID-19. "Sanofi is supporting ongoing trials by providing the medicine to some participating investigator sites and other independent research centres," it said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 21,2020

Beijing, Mar 21: China reported no domestically transmitted coronavirus cases for the third consecutive day even as seven more fatalities have been confirmed, taking the death toll in the country to 3255.

No new domestically transmitted cases of COVID-19 were reported on the Chinese mainland for the third day in a row on Friday, China's National Health Commission (NHC) said on Saturday.

The overall confirmed cases on the mainland had reached 81,008 by the end of Friday, which included 3,255 who died, 6,013 patients still undergoing treatment, 71,740 patients who had been discharged after recovery, the NHC said.

The NHC said 41 new confirmed COVID-19 cases were reported on the Chinese mainland on Friday from the people arriving from abroad, taking the total number of imported cases to 269.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.